About Viveve Medical (NASDAQ:VIVE)
Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.
Industry, Sector and Symbol:
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:VIVE
- Previous Symbol: OTCMKTS:PLCSD
- CUSIP: N/A
- Web: www.viveve.com
- Debt-to-Equity Ratio: 2.72%
- Current Ratio: 3.89%
- Quick Ratio: 3.63%
Sales & Book Value:
- Annual Sales: $7.14 million
- Price / Sales: 13.55
- Book Value: ($0.04) per share
- Price / Book: -124.50
- Trailing EPS: ($2.16)
- Net Income: ($20,110,000.00)
- Net Margins: -257.58%
- Return on Equity: -275.77%
- Return on Assets: -102.12%
- Employees: 42
- Outstanding Shares: 19,430,000
Frequently Asked Questions for Viveve Medical (NASDAQ:VIVE)
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical, Inc. (NASDAQ:VIVE) announced its earnings results on Wednesday, November, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.08. The firm had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company's quarterly revenue was up 120.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.46) EPS. View Viveve Medical's Earnings History.
Where is Viveve Medical's stock going? Where will Viveve Medical's stock price be in 2017?
5 brokers have issued 1-year target prices for Viveve Medical's stock. Their forecasts range from $10.00 to $11.00. On average, they expect Viveve Medical's stock price to reach $10.40 in the next twelve months. View Analyst Ratings for Viveve Medical.
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include Cytosorbents Corporation (CTSO), Cogentix Medical (CGNT), Alliance HealthCare Services (AIQ), Harvard Bioscience (HBIO), IRIDEX Corporation (IRIX), EDAP TMS S.A. (EDAP), Neovasc (NVCN), Presbia PLC (LENS), Fulgent Genetic (FLGT), Luna Innovations Incorporated (LUNA), Digirad Corporation (DRAD), InVivo Therapeutics Holdings Corp. (NVIV), Electromed (ELMD), Biolase (BIOL), Advanced Oncotherapy PLC (AVO), EnteroMedics (RSLS), Dynatronics Corporation (DYNT) and Dextera Surgical (DXTR).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- James G. Atkinson, Chief Business Officer and President (Age 59)
- Patricia K. Scheller, Chief Executive Officer, Director (Age 57)
- Scott C. Durbin, Chief Financial Officer (Age 48)
- Lori H. Bush, Independent Director (Age 60)
- Daniel S. Janney, Lead Independent Director (Age 51)
- Debora A. Jorn, Independent Director (Age 59)
- Arlene M. Morris, Independent Director (Age 65)
- Jon M. Plexico, Independent Director (Age 49)
When did Viveve Medical IPO?
(vive) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
Who owns Viveve Medical stock?
Viveve Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include RTW Investments LP (7.58%), Perceptive Advisors LLC (2.51%), ING Groep NV (1.67%), Granahan Investment Management Inc. MA (0.53%) and Neuberger Berman Group LLC (0.41%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Institutional Ownership Trends for Viveve Medical.
Who sold Viveve Medical stock? Who is selling Viveve Medical stock?
Who bought Viveve Medical stock? Who is buying Viveve Medical stock?
Viveve Medical's stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, ING Groep NV, Neuberger Berman Group LLC and Granahan Investment Management Inc. MA. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Insider Buying and Selling for Viveve Medical.
How do I buy Viveve Medical stock?
Shares of Viveve Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of Viveve Medical stock can currently be purchased for approximately $4.98.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $96.74 million and generates $7.14 million in revenue each year. The company earns ($20,110,000.00) in net income (profit) each year or ($2.16) on an earnings per share basis. Viveve Medical employs 42 workers across the globe.
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Viveve Medical (NASDAQ:VIVE) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$10.40 (108.84% upside)|
Consensus Price Target History for Viveve Medical (NASDAQ:VIVE)
Analysts' Ratings History for Viveve Medical (NASDAQ:VIVE)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|11/16/2017||Mizuho||Initiated Coverage||Buy -> Buy||$10.00||N/A|
|10/23/2017||Cowen and Company||Set Price Target||Buy||$11.00||N/A|
|8/11/2017||Maxim Group||Reiterated Rating||Buy||$11.00||High|
|5/25/2017||Raymond James Financial, Inc.||Initiated Coverage||Outperform -> Outperform||$10.00||Medium|
|5/17/2017||B. Riley||Reiterated Rating||Buy||$10.00||Medium|
|9/20/2016||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$22.00||N/A|
Earnings History and Estimates Chart for Viveve Medical (NASDAQ:VIVE)
Earnings History by Quarter for Viveve Medical (NASDAQ VIVE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.42)||($0.50)||$4.10 million||$4.07 million||View||N/A|
|8/10/2017||Q2 2017||($0.33)||($0.54)||$3.24 million||$3.08 million||View||N/A|
|5/11/2017||Q1 2017||($0.51)||($0.57)||$2.70 million||$3.04 million||View||N/A|
|11/10/2016||Q316||($0.48)||($0.46)||$1.70 million||$1.85 million||View||N/A|
|8/11/2016||Q216||($0.48)||($0.66)||$1.33 million||$1.56 million||View||Listen|
Earnings Estimates for Viveve Medical (NASDAQ:VIVE)
2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.17)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Viveve Medical (NASDAQ:VIVE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Viveve Medical (NASDAQ VIVE)
Insider Ownership Percentage: 35.10%
Institutional Ownership Percentage: 65.92%
Insider Trades by Quarter for Viveve Medical (NASDAQ VIVE)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/23/2017||Scott Durbin||CFO||Buy||5,000||$5.25||$26,250.00|| |
|3/17/2017||James G Atkinson||Director||Buy||375,000||$4.00||$1,500,000.00|| |
|3/17/2017||Patricia Scheller||CEO||Buy||12,500||$4.00||$50,000.00|| |
|6/17/2016||James G. Atkinson||Insider||Buy||100,000||$5.00||$500,000.00|| |
|6/17/2016||Patricia Scheller||CEO||Buy||6,000||$5.00||$30,000.00|| |
|6/17/2016||Scott Durbin||CFO||Buy||1,500||$5.00||$7,500.00|| |
|6/17/2016||Stonepine Capital Management,||Major Shareholder||Buy||300,000||$5.00||$1,500,000.00|| |
|9/23/2014||5Am Partners Ii, Llc||Major Shareholder||Buy||5,215,664||$0.53||$2,764,301.92|| |
|9/23/2014||Daniel Janney||Director||Buy||1,895,788||$0.53||$1,004,767.64|| |
Latest Headlines for Viveve Medical (NASDAQ VIVE)
|Viveve Medical (VIVE) Presents At 8th Annual Craig-Hallum Alpha Select Conference - Slideshow|
seekingalpha.com - November 18 at 10:04 AM
|Viveve Medical, Inc. (VIVE) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - November 16 at 9:54 PM
|Viveve Medical, Inc. (VIVE) Research Coverage Started at Mizuho|
www.americanbankingnews.com - November 16 at 7:47 PM
|ETFs with exposure to Viveve Medical, Inc. : November 10, 2017|
finance.yahoo.com - November 12 at 1:11 PM
|Edited Transcript of VIVE earnings conference call or presentation 8-Nov-17 10:00pm GMT|
finance.yahoo.com - November 12 at 1:11 PM
|Reviewing Derma Sciences (DSCI) and Viveve Medical (VIVE)|
www.americanbankingnews.com - November 9 at 11:06 PM
|Viveve Announces Third Quarter 2017 Financial Results|
finance.yahoo.com - November 9 at 9:32 AM
|Viveve Medical, Inc. (VIVE) Issues Earnings Results|
www.americanbankingnews.com - November 8 at 9:10 PM
|Comparing Viveve Medical (VIVE) and Its Rivals|
www.americanbankingnews.com - November 7 at 7:22 PM
|Viveve to Present at November Investor Conferences|
finance.yahoo.com - November 2 at 10:55 AM
|Viveve Launches GENEVEVE(TM) by Viveve Treatment in Canada|
www.marketwatch.com - November 1 at 10:24 AM
|Viveve Medical (VIVE) and The Competition Head-To-Head Analysis|
www.americanbankingnews.com - October 27 at 9:39 AM
|Streetwise Reports Examines Biotech Company that Receives Device Approval in Five More Countries and Revenue Increases 122% YOY|
finance.yahoo.com - October 26 at 11:51 AM
|Viveve Medical, Inc. (VIVE) Given a $11.00 Price Target at Cowen and Company|
www.americanbankingnews.com - October 24 at 3:32 PM
|VIVE: Q3 Revenue Beats, Details Imply Strong Q4|
finance.yahoo.com - October 24 at 12:06 PM
|BRIEF-Viveve gets regulatory nod to market Viveve System in Mexico|
www.reuters.com - October 18 at 10:18 AM
|Viveve Releases Preliminary Third Quarter 2017 Financial Results|
feeds.benzinga.com - October 18 at 8:55 AM
|ETFs with exposure to Viveve Medical, Inc. : October 16, 2017|
finance.yahoo.com - October 17 at 8:50 AM
|Viveve Announces Regulatory Approval for Viveve System in Mexico|
finance.yahoo.com - October 17 at 8:50 AM
| Analysts Anticipate Viveve Medical, Inc. (VIVE) Will Post Quarterly Sales of $3.63 Million|
www.americanbankingnews.com - October 15 at 3:56 AM
|Head-To-Head Review: Viveve Medical (VIVE) vs. Its Rivals|
www.americanbankingnews.com - October 13 at 8:26 AM
|Viveve Medical, Inc. :VIVE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017|
finance.yahoo.com - October 6 at 12:29 PM
|ETFs with exposure to Viveve Medical, Inc. : October 5, 2017|
finance.yahoo.com - October 6 at 12:29 PM
|Viveve to Present at the Ladenburg Thalmann 2017 Healthcare Conference|
finance.yahoo.com - September 19 at 9:22 AM
|Viveve Medical (VIVE) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow|
seekingalpha.com - September 13 at 8:57 PM
|BRIEF-Viveve announces additional regulatory approvals in Middle East|
www.reuters.com - September 12 at 11:50 AM
|Viveve Announces Additional Regulatory Approvals in Middle East|
finance.yahoo.com - September 12 at 11:50 AM
|Earnings Review and Free Research Report: Medtronic's Q1 Non-GAAP EPS Grew 9% Y-o-Y; Topped Expectations|
finance.yahoo.com - September 11 at 8:17 AM
|Form 4 VIVEVE MEDICAL, INC. For: Sep 06 Filed by: Morris Arlene|
www.streetinsider.com - September 9 at 9:44 AM
|Viveve Medical, Inc. (VIVE) Expected to Announce Quarterly Sales of $3.63 Million|
www.americanbankingnews.com - September 8 at 8:20 AM
|Viveve to Present at the 19th Annual Rodman & Renshaw Global Investment Conference|
finance.yahoo.com - September 6 at 9:53 AM
|LeMaitre Vascular (LMAT) and Viveve Medical (VIVE) Head-To-Head Analysis|
www.americanbankingnews.com - September 5 at 8:46 PM
|Viveve Medical, Inc. (VIVE) Receives Average Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - September 5 at 8:48 AM
|Viveve Medical (VIVE) vs. Varian Medical Systems (VAR) Head-To-Head Analysis|
www.americanbankingnews.com - September 1 at 9:02 AM
|Head to Head Comparison: ResMed (RMD) & Viveve Medical (VIVE)|
www.americanbankingnews.com - September 1 at 4:16 AM
|Viveve Medical, Inc. (VIVE) CFO Buys $26,250.00 in Stock|
www.americanbankingnews.com - August 23 at 8:50 PM
|VIVE: Anticipating IDE Approval, Utilization Jumps|
finance.yahoo.com - August 23 at 1:32 PM
|Viveve Medical, Inc. (VIVE) PT Set at $11.00 by Cowen and Company|
www.americanbankingnews.com - August 20 at 7:32 PM
|-$0.43 EPS Expected for Viveve Medical, Inc. (VIVE) This Quarter|
www.americanbankingnews.com - August 18 at 8:10 PM
|Viveve Medical, Inc. (NASDAQ:VIVE) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - August 11 at 7:00 PM
|Viveve Medical's (NASDAQ:VIVE) Buy Rating Reiterated at Maxim Group|
www.americanbankingnews.com - August 11 at 4:58 PM
|Edited Transcript of VIVE earnings conference call or presentation 10-Aug-17 9:00pm GMT|
finance.yahoo.com - August 11 at 3:49 PM
|BRIEF-Viveve Medical reports Q2 loss per share $0.54|
www.reuters.com - August 10 at 8:40 PM
|Viveve Announces Second Quarter 2017 Financial Results and Strategic Partnership with InControl Medical, LLC|
finance.yahoo.com - August 10 at 8:40 PM
|Streetwise Reports Examines How Loan Provides Driver for Growth for Medical Device Firm|
finance.yahoo.com - August 9 at 8:55 AM
|Viveve to Announce Second Quarter 2017 Financial Highlights|
finance.yahoo.com - August 4 at 9:42 AM
|Viveve Medical, Inc. (NASDAQ:VIVE) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - August 2 at 7:22 AM
|-$0.34 Earnings Per Share Expected for Viveve Medical, Inc. (NASDAQ:VIVE) This Quarter|
www.americanbankingnews.com - July 31 at 2:20 PM
|ETFs with exposure to Viveve Medical, Inc. : July 13, 2017|
finance.yahoo.com - July 14 at 9:45 AM
|$3.29 Million in Sales Expected for Viveve Medical, Inc. (VIVE) This Quarter|
www.americanbankingnews.com - July 9 at 9:46 AM
Viveve Medical (NASDAQ VIVE) Chart for Sunday, November, 19, 2017